Compare CLRB & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRB | CLPS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 28.9M |
| IPO Year | 2008 | 2017 |
| Metric | CLRB | CLPS |
|---|---|---|
| Price | $1.18 | $0.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 148.1K | 6.5K |
| Earning Date | 11-12-2026 | 10-16-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $0.80 |
| 52 Week High | $4.70 | $1.24 |
| Indicator | CLRB | CLPS |
|---|---|---|
| Relative Strength Index (RSI) | 25.04 | 46.04 |
| Support Level | N/A | $0.97 |
| Resistance Level | $3.03 | $1.04 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 12.69 | 45.04 |
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
CLPS Inc is information technology, consulting and solutions service provider, focused on delivering services mainly to world-wide institutions, including banking, wealth management, ecommerce, and automotive areas both in China and globally. It has been at the forefront of driving digital transformation and optimizing operational efficiency across industries through innovations in artificial intelligence (AI), cloud computing, and data. It diverse business lines span sectors including fintech, payment and credit services, e-commerce, education and study abroad programs, and world-wide tourism integrated with transportation services. Its segments are IT services and academic education service. Majority of revenue comes from IT services segment. Its products are NiBot RPA, and CAKU.